Tag:

Pfizer

Latest Headlines

Latest Headlines

Rumor mill churning as possible Pfizer/AstraZeneca Round 2 approaches

Rumors about a potential new phase of the Pfizer/AstraZeneca takeover saga just won't go away, with all the talk giving the U.K. pharma's share price a lift this week.

Round two? Market rumors on a new Pfizer bid for AstraZeneca heat up

The story about a potential new takeover offer for AstraZeneca by Pfizer will not die.

Pfizer's C. diff vaccine gains on Sanofi with FDA fast-track nod

Look out, Sanofi. Pfizer's Clostridium difficile candidate has just nabbed an FDA fast-track designation that should help it pick up some ground in the race to bring the first vaccine for the disease to market.

Does Pfizer still need AstraZeneca's vaccines business?

Earlier this year, when Pfizer made a play for rival pharma giant AstraZeneca, CEO Ian Read listed the British drugmaker's vaccines portfolio as a motivating factor. Now, rumors are swirling that the company could be eyeing Actavis as a backup plan. On the one hand, the New Jersey generics maker lacks vaccines offerings. And on the other, with the recent developments affecting Pfizer's unit, how much does that matter?

It's official: The Pfizer-AstraZeneca deal talk can resume

Let the speculation continue: The window to another Pfizer-AstraZeneca bidding round is now open, per U.K. takeover rules.

Looking for a Xalkori boost, Pfizer adds targeted med to Merck IO pact

Pfizer isn't among the leaders in the hot immuno-oncology field. But the company is friends with one of them--Merck. And now, Pfizer has tied yet another cancer treatment to Merck's IO coattails.

Pfizer and Merck extend heavyweight immuno-oncology pact to lung cancer

Merck and Pfizer have struck a deal to add the immuno-oncology superstar pembrolizumab to Xalkori for ALK-positive cases of advanced non-small cell lung cancer.

Pfizer-AstraZeneca sequel could hit theaters next week

Months removed from an intercontinental M&A dance that polarized investors and paralyzed executives, Pfizer and AstraZeneca will soon be free to start talking about a deal once more, provided the latter company is interested.

Pfizer, BMS pad bright Q2 with new FDA nod for Eliquis

Pfizer and Bristol-Myers Squibb's Eliquis has been lagging since launch time, trailing behind predecessors Pradaxa and Xarelto. But lately, the drugmakers' efforts have been paying off when it comes to market share, and a new indication may help keep the ball rolling.

Lilly's strong results for psoriasis drug come on heels of data from Novartis

Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab when compared with Pfizer's Enbrel in a head-to-head study.